VanEck Biotech ETF (NASDAQ:BBH) Sees Significant Decline in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 600 shares, a decline of 45.5% from the October 15th total of 1,100 shares. Based on an average daily trading volume, of 4,300 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On VanEck Biotech ETF

Hedge funds have recently bought and sold shares of the business. Truvestments Capital LLC purchased a new stake in shares of VanEck Biotech ETF in the third quarter valued at approximately $44,000. Mather Group LLC. purchased a new stake in VanEck Biotech ETF in the 2nd quarter worth $46,000. Red Lighthouse Investment Management LLC acquired a new position in VanEck Biotech ETF during the second quarter worth $51,000. Coastline Trust Co purchased a new position in VanEck Biotech ETF during the third quarter valued at $59,000. Finally, Hyman Charles D purchased a new position in VanEck Biotech ETF during the second quarter valued at $202,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

BBH stock opened at $169.31 on Thursday. VanEck Biotech ETF has a 52-week low of $148.52 and a 52-week high of $183.64. The company’s 50-day simple moving average is $175.56 and its 200-day simple moving average is $173.08.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.